Drug Delivery

Popular drug delivery methods are non-invasive such as through the mouth, topical (on the skin), ocular, vaginal etc. although not all drugs can be transferred via non-invasive methods, such as protein, which requires delivery by injecting it to the blood circulation.

The most popular method of consuming drugs was and still is orally (pills and liquids).

 

One of the challenging aspects of drug delivery is adjusting these methods to the nature of the drug and the areas and functionalities in the human body that it adheres to tackle.

 

Therefore, the main goal of drug delivery systems is to deploy medications intact to specific parts in the body via a source that can assist controlling and monitoring its effect and success. Thus when referring to drug delivery systems, scientists are attempting to address the problem of reduced therapeutic effects that are caused due to degradation that occurs in the effect of the drug prior it reaching the desired part in the body. One of the solutions to this problem might have been an attempt to locate different targeted areas in the body to inject the drug to, but it may arouse other problems for different areas in the body react differently to different types of medication. (for instance in the stomach, due to low Ph, a medication can be destroyed).

 

The world of nanotechnology – polymeric microspheres, polymer micelles and hydrogel-type materials have proven to be greatly efficient in dealing with drug absorption rates, toxicity etc.

 

The polymeric materials are most popular routes for drug delivery systems research, mainly because the relatively easiness of controlling their chemical and physical properties by researchers.  

 

 

 

Delivery Mechanisms for Large Molecule Drugs Successes and failures of leading technologies and key drivers for market success

Aarkstore announce a new report  “Delivery Mechanisms for Large Molecule Drugs Successes and failures of leading technologies and key drivers for market success” through its vast collection of market research report.

Delivery Mechanisms for Large Molecule Drugs Successes and failures of leading technologies and key drivers for market success

Emerging drug delivery technologies aim to improve measures of safety, efficacy, convenience and compliance in both new and existing drug candidates and products. For currently marketed products, reformulations with new delivery technologies will extend the period of patent protection. New formulas will be key to boosting sales volume of large molecule products in chronic diseases where patient compliance surrounding dosing strategies and ease of administration are limitations on market growth. In R&D pipelines, novel applications of delivery technologies will expose new methods to reformulate failed or discontinued drugs and mask their unfavorable effects, expanding the market of potential drug candidates.

‘Delivery Mechanisms for Large Molecule Drugs’ is a report examines the future of the drug delivery technologies market, and the short, mid, and long-term growth dynamics which will underpin investment decisions. This report will measure the performance of leading drug delivery technologies applied within clinical R&D pipelines and identify when specific therapy area populations are set to benefit from emerging innovations. The market success of new technologies is forecast by their ability to fulfill unmet medical need, the maturity of the technology in clinical application, and the level of commercial interest and investment landscape.

Key Findings

Nanotechnology will have the greatest impact on the drug delivery market. However, the immaturity of the technology is likely to delay marketed presence over the next 7-10 years.

Antibody fragmentation and PEGylation technologies are the leading targeted large molecule particle engineering formulas with marketed drug product presence. However, antibody fragments have suffered 33 candidate failures compared with 12 PEGylated products.

Active transdermal technologies have generated the greatest number of technologies and devices amongst large molecule delivery innovations, with 16 clinical and 8 preclinical drug/device combination products and 49 stand-alone devices.

Electronic delivery is set to have the greatest impact upon the device industry. Electronic device control is more advanced within the field of pulmonary delivery than transdermal delivery, with the average pulmonary-based product in early clinical phase I compared to late-stage preclinical investigation for transdermal. There are, however, 25 transmembrane electroporation technologies currently being developed, in comparison to 12 for electronic active pulmonary delivery.

Use this report to…

Understand the drivers of new delivery platform developments with this report’s analysis of therapy area growth drivers, clinical development spend and unmet clinical need.

Identify the risks and opportunities associated with emerging delivery technologies by measuring the risk potential and maturity of innovative platforms.

Evaluate the latest developments in systemic targeting technologies by using this report’s analysis of innovations and pipeline progress for the latest active and passive targeting techniques.

Discover which technologies have the greatest potential within large molecule product markets in the future with this report’s comparative analysis of growth metrics for leading platforms and an evaluation of their established clinical drug application.

Assess recent innovations in pulmonary delivery technologies and needle-free transdermal delivery with this report’s analysis of clinical and preclinical developments and commercial potential.

Explore issues including…

High failure rates for new technologies. The high failure rates of drugs to which pioneering delivery techniques have been applied have made investors cautious.

Unknown clinical safety and efficacy profiles have made it harder to determine appropriate parameters for success in clinical application.

Immaturity of technologies. Many of the technology platforms profiled in this report are in the early stages of application to clinical drug candidates. Those that have achieved success in marketed drug candidates already have ‘next generation’ alternatives in technology pipelines.

Unknown clinical pharmacokinetics. Many of these platforms remain in such an immature stage that they have yet to be applied to drug candidates. In vivo experimental use in drug candidates can never accurately predict success once a technology has reached maturity. Even for those technologies with established use in R&D pipelines, long-term clinical efficacy remains unknown.

Regulation of the new technologies. While the clinical performance of new particle engineered drug molecules or active delivery devices remain unknown, regulatory bodies only have existing data-measure demands on which to benchmark their expectations. This framework will be shifted in line with emerging clinical performance datasets.

Discover…

Which delivery technologies will have the greatest impact on the large molecule market in the short, mid, and long-term?

How mature are the different delivery technologies and what is their pipeline presence in terms of application to R&D drugs?

Will particle engineering technologies drive injectable formulas to dominate the market?

Which therapy areas will benefit most from growth in the different technologies?

How can the risk-profiles associated with clinical use be most effectively minimized?

What are the leading novel platforms?

Who are the targets for out-licensing and co-development of platforms for clinical use?

What are the leading technology platforms within different classifications and how have they achieved their growth?

For more information, please visit :
http://www.aarkstore.com/reports/Delivery-Mechanisms-for-Large-Molecule-Drugs-Successes-and-failures-of-leading-technologies-and-key-drivers-for-market-success-13939.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

Drug Delivery Markets: Implantable / Injectable And Needle-Free Delivery Systems

With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets.

Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports current and forecasted revenues for the implantable/injectable drug delivery market, segmented into two main categories:

Needle-free drug delivery

Other Injectable/Implantable

Kalorama’s unique analysis offers segmentation of this market for:

Drug Delivery Technology Revenues

Pharmaceuticals Sold via Delivery Technology

This breakout makes the report relevant to business plans of either device technology companies or pharmaceutical concerns. (This market analysis does not include drug-eluding stents or prefilled or regular syringes. Kalorama considers these separate markets)

The report covers both pharmaceuticals sold through implantable/injectable delivery systems and the technologies themselves including:

Detailed Profiles of Key Companies in Implantable/Injectable Delivery

Brief Round-Up of Smaller Players

Current Market Size and Forecasts to 2013

Needle-Free Cost Savings, Protein-Coated Microcrystal Technology, Nanotechnology, and Other Trends and Developments

Revenue Forecasts

New Products in Development

Kalorama’s trusted information-gathering process provides most accurate study of the implantable/injectable delivery drug market available today. Information and analysis presented in this report is based on extensive interviews with senior management of top companies in the industry. While major research literature and government information is culled, information is corroborated and key market insights originate from interviews with industry leaders.

Companies Profiled in the report include:

Alkermes, Inc.

ALZA Corp.

Antares Pharma, Inc.

Bioject Medical Technologies, Inc.

CyDex, Inc.

MGI Pharma, Inc

Nektar Therapeutics

Pacira Pharmaceuticals, Inc.

pSivida

SurModics, Inc

Zogenix Corporation

AP Pharma

Baxter BioPharma Solutions

QLT USA, Inc

Ypsomed Holding AG

Kalorama has also published Drug Delivery Markets: Oral Delivery, which details markets for oral technology enhancements which have increased drug product sales and extended patent life.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1655/Drug-Delivery-Markets-Implantable-Injectable-and-Needle-Free-Delivery-Systems.html

Contact Us:

Visionshopsters
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Innovations in Drug Delivery

The drug delivery industry has emerged significantly with the time. The process of dealing with pharmaceutical compounds to accomplish a healing effect in humans or animals is known as drug delivery. Advanced drug delivery systems assure better delivery of drug into the body.

 

In terms of healthcare industry, drug delivery is the fastest growing sector. Current findings in the drug delivery sector highlight the development of targeted and advanced drug delivery systems. Here, drug is activated only in the infected parts of the body.

 

Innovations:

 

Drug delivery technology along with advancing with time has a positive impact on the global pharmaceutical industry. This is evidence from the immense applications of drug delivery technology around the world.

 

It offers matchless opportunities to fight diseases in an effective way. In fact, a proper drug delivery system helps in eliminating issues such as tolerability, side effects and multiple applications.

 

Drug delivery systems can boost a drug’s medicinal value by offering pharmacological benefits as compared to conventional products available in the market. Drug delivery systems evolved greatly from mere reformulation in a quick span of time.

 

Novel drug delivery technologies offer new potencies to come up with new solutions for new medical problems. Some of the novel drug delivery systems are as follows:

 

Self-emulsifying drug delivery  systems Nanotechnology-enabled formulations for delivery of poorly water-soluble drugs Innovative drug delivery  solutions for Biotech-derived products Sustained Release Formulations Micro/Nano particulate drug delivery  systems Intra-nasal drug delivery systems

 

There is also great advancement in such new drug delivery systems. For instance, transdermal drug delivery has the ability to make use of nanotechnology to increase concentration and bioavailability.

 

These types of drug delivery methods can be highly useful for patients suffering from central nervous system (CNS) or neurodegenerative disorders.

Learn About Drug Delivery Systems

Drug delivery is a process, during which pharmaceutical compounds are delivered to humans or animals. Methods of delivery include several routs, such as oral, nasal, pneumonial, rectal and several others. In order to work effectively, the drug needs to work in a controlled manner, which would control the circulation of the drug in the body. Targeted delivery occurs when the drug remains active within a specified territory of the body. Targeted drug delivery is especially important in cases, when the drug needs to affect a malicious turmoil, such as in cancerous tissues.

Doctors all over the world are trying to find new methods for more effective drug development and drug delivery systems. One of the most successful methods developed in recent years is nanotechnology. This mechanism, which controls small-scale matter, makes it possible for drugs to permeate trough cell walls. The methods of nanotechnology play a very important role in pharma industry: health organizations manufacture more efficient drugs, released in a controlled manner in order to reach the target areas of the patients’ body.

Drug development aims to find more effective drugs, which would cure or ameliorate symptoms of illness or medical condition. Drug development is required to establish the chemical properties of new compounds, their stability and chemical makeup. The process of drug development also involves the need to fit the regulatory requirements of drug licensing authorities. Pharmaceutical companies, which produce different medications, develop new methods of targeted drug delivery. Nanotechnology, developed in recent years may provide a breakthrough technique of drug delivery.

« Previous Page — Next Page »